Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications

Cancer Biomarkers

Volumn 5, Issue 3, 2009, Pages 137-142

  Lee, Gregory ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CA215; Cancer cell expressed immunoglobulins; Carbohydrate associated epitope; In vitro diagnostics; Monitoring of human cancers; Pan cancer marker; RP215 monoclonal antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CANCER CELL EXPRESSED IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RP215; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANTIGENS, NEOPLASM; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; IMMUNOASSAY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 65449179863     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0610     Document Type: Article

References (14)

1. R.C. Bast, D. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu et al., New tumor markers: CA125 and beyond, Int J Gynecol Cancer 15 suppl.3) (2005), 274-281.
2. R.C. Bast Jr, T.L. Klug, E. St John, E. Jenison, J.M. Niloff, H. Lazarus et al., Radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Eng J Med 309 (1983 , 883-887.
3. R.C. Bast Jr, T.L. Klug, E. Schaetzl, P. Lavin, J.M. Niloff, T.F. Greber et al, Monitoring human ovarian carcinoma with a combination of CA125, CA19-9 and carcinoembryonic antigen, Am J Obstet, Gynecol 149 (1984), 553-559.
4. S.N. Chow, B. Ho-Yuen and C.Y.G Lee, Application of monoclonal antibodies in immunoassays of human luteinizing hormone, J Appl Biochem 7 (1985), 114-118.
5. H. Kato, K. Tamai, H. Morioka, M. Nagai, T. Nagaya and T. Torigoe, Tumor antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma, Cancer 54 (1984), 1544-1546.
6. S. Knauf, D.J. Anderson, R.C. Knapp and R.C. Bast Jr, A study of the NB/ 70K and CA125 monoclonal antibody radioimmunoassay for measuring serum antigen levels in ovarian cancer patients, Am J Obstet Gynecol 152 (1985), 911-913.
7. S. Knauf and R.C. Bast Jr, Tumor antigen NB/70K and CA125 levels in the blood of preoperative ovarian cancer patients and controls: A preliminary report of the use of the NB12123 and CA125 radioimmunoassays alone and in combination, Int J Biol Markers 3 (1988), 75-81.
8. C.Y.G. Lee, K.W. Chen, F.S. Sheu, A. Tsang, K.C. Chao and H.T. Ng, Studies of a tumor- associated antigen, COX- 1, recognized by a monoclonal antibody, Cancer Immunol Immunother 35 (1992), 19-26.
9. G. Lee, R.Y. Chu and H.H. Ting, Preclinical assessment of anti-cancer drugs by using RP215 monoclonal antibody, Cancer Biology and Therapy (in press).
10. G. Lee, E. Laflamme, C.H. Chien and H-H. Ting, Molecular identity of a pan cancer marker, CA215, Cancer Biology and Therapy 7 (2008), 91-98.
11. C.Y.G Lee and H.T. Ng, Clinical evaluation of a new ovarian cancer marker, COX-1, Int J Gynecol Obstet 49 (1995), S27-S32.
12. G. Lee, Q. Wu, C-H. Li, H-H. Ting and C.H. Chien, Recent studies of a new carbohydrate-associated pan cancer marker, CA215, J Clin Ligand Assay 29 (2006), 47-51.
13. T. Maruo, K. Shibata, A. Kimura, M. Hoshina and M. Mochizuki, Tumor-associated antigen, TA-4 in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix, Cancer 56 (1985), 302-308.
14. S.J. Skates, N. Horick, Y. Yu, F.J. Xu, A. Berchuck, L.J. Havrilesky et al., Preoperative sensitivity and specificity for early-stage ovarian cancer when combining CA125, CA15.3, CA72.4 and M-CSF using mixtures of multivariate normal distributions, J Clin Oncol 22 (2004), 4059-4066.